| [1] |
LOCOCO F. Malignant pleural mesothelioma: Time is running out[J]. J Clin Med, 2021, 10(4): 648. DOI: 10.3390/JCM10040648. |
| [2] |
RINGGAARD PETERSEN T, PANOU V, MERISTOUDIS C, et al. Clinical prognostic factors in pleural mesothelioma: Best supportive care and anti-tumor treatments in a real-life setting[J]. Acta Oncol, 2021, 60(4): 521-527. DOI: 10.1080/0284186X.2021.1876246. |
| [3] |
LETTIERI S, BORTOLOTTO C, AGUSTONI F, et al. The evolving landscape of the molecular epidemiology of malignant pleural mesothelioma[J]. J Clin Med, 2021, 10(5): 1034. DOI: 10.3390/jcm10051034. |
| [4] |
CHANG H, YU ZY, WANG QM, et al. Clinical characteristics and diagnostic analysis of 120 cases with malignant pleural mesothelioma[J]. Tumor, 2020, 40(3): 199-205, 214. DOI: 10.3781/j.issn.1000-7431.2020.33.006. |
| [5] |
LEE DS, CAROLLO A, ALPERT N, et al. VATS pleurectomy decortication is a reasonable alternative for higher risk patients in the management of malignant pleural mesothelioma: An analysis of short-term outcomes[J]. Cancers (Basel), 2021, 13(5): 1068. DOI: 10.3390/cancers13051068. |
| [6] |
LOMBARD A, MISTRY H, CHAPMAN SC, et al. Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed[J]. Eur J Pharm Sci, 2021, 161(1): 105781. DOI: 10.1016/j.ejps.2021.105781. |
| [7] |
KHALIQ MF, NOORANI MM, CHOWDHRY M, et al. Transjugular intrahepatic portosystemic shunt (TIPS) in refractory transudative chylothorax due to liver cirrhosis[J]. Case Rep Med, 2020, 2020: 2581040. DOI: 10.1155/2020/2581040. |
| [8] |
|
| [9] |
WANG Y, WANG M, ZHANG GH, et al. Clinical diagnosis, staging, and therapeutic principles of liver cirrhosis[J]. J Clin Hepatol, 2021, 37(1): 17-21. DOI: 10.3969/j.issn.1001-5256.2021.01.004. |
DownLoad:
